Paul A Friedman

Paul A Friedman has an estimated net worth of $1.17 Billion. This is based on reported shares across multiple companies, which include MADRIGAL PHARMACEUTICALS, INC., Sirtris Pharmaceuticals, Inc., Prelude Therapeutics Inc, Verastem, Inc., Cerulean Pharma Inc., Durata Therapeutics, Inc., AUXILIUM PHARMACEUTICALS INC, ALEXION PHARMACEUTICALS, INC., BAUSCH & LOMB INC, and INCYTE CORP.

2014 was Paul A Friedman's most active year for acquiring shares with 23 total transactions. Paul A Friedman's most active month to acquire stocks was the month of April. 2025 was Paul A Friedman's most active year for disposing of shares, totalling 55 transactions. Paul A Friedman's most active month to dispose stocks was the month of December. 2015 saw Paul A Friedman paying a total of $8,403,941.68 for 604,520 shares, this is the most they've acquired in one year. In 2014 Paul A Friedman cashed out on 2,052,241 shares for a total of $66,346,814.02, their largest year based on trade value.